Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

First Posted Date
2009-08-10
Last Posted Date
2017-04-20
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
32
Registration Number
NCT00955474
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients

Phase 3
Completed
Conditions
Interventions
First Posted Date
2009-08-06
Last Posted Date
2013-02-12
Lead Sponsor
Ludwig-Maximilians - University of Munich
Target Recruit Count
60
Registration Number
NCT00953108
Locations
🇩🇪

Department of Psychiatry, Ludwig-Maximilian-University, Munich, Bavaria, Germany

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

First Posted Date
2009-08-06
Last Posted Date
2018-04-19
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
43
Registration Number
NCT00953745
Locations
🇺🇸

Washington University in St. Louis, School of Medicine, Saint Louis, Missouri, United States

Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment

Phase 3
Conditions
Interventions
First Posted Date
2009-07-09
Last Posted Date
2009-09-02
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
100
Registration Number
NCT00935675
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

First Posted Date
2009-07-08
Last Posted Date
2015-12-31
Lead Sponsor
Samsung Medical Center
Target Recruit Count
202
Registration Number
NCT00935246
Locations
🇰🇷

Samsung Medical Center, Kangnam, Seoul, Korea, Republic of

Assessing Anterior Cingulate Brain Activity in People With Late-Life Depression

Completed
Conditions
Interventions
First Posted Date
2009-06-23
Last Posted Date
2015-08-11
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
76
Registration Number
NCT00926653
Locations
🇺🇸

New York Presbyterian-Weill Cornell Medical College, White Plains, New York, United States

Aging Brain Changes, Executive Dysfunction and Depression

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-06-11
Last Posted Date
2017-05-12
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
116
Registration Number
NCT00918684

Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-06-10
Last Posted Date
2013-02-06
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
172
Registration Number
NCT00917059
Locations
🇺🇸

UCLA Semel Institute, Los Angeles, California, United States

Escitalopram in Patients With Social Anxiety Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-05-15
Last Posted Date
2011-06-10
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
30
Registration Number
NCT00902226
Locations
🇷🇺

RU001, Moscow, Russian Federation

© Copyright 2024. All Rights Reserved by MedPath